Chimerix

News Releases

2010

Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus

   

New Broad-Spectrum Antiviral Agent to Be Evaluated for Preventative and Therapeutic Activity

RESEARCH TRIANGLE PARK, NC, March 9, 2010 – Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a… > Read More

Chimerix CEO George Painter, Ph.D., to Speak at Institute of Medicine Workshop

   

RESEARCH TRIANGLE PARK, NC, February 23, 2010 - Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that founder and CEO George Painter, Ph.D., will join representatives from government, industry and academia… > Read More

Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer

   

RESEARCH TRIANGLE PARK, NC, February 04, 2010 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.

Dr.… > Read More

2009

Chimerix to Present at Two Upcoming Investor Conferences

   

RESEARCH TRIANGLE PARK, NC, November 12, 2009 – Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a… > Read More

Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox

   

RESEARCH TRIANGLE PARK, NC, November 6, 2009 - Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's lead antiviral compound, CMX001,… > Read More

Chimerix Raises $16.1 Million in Series E Financing

   

RESEARCH TRIANGLE PARK, NC, August 11, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, today announced the completion of a $16.1 million Series E financing.  Leading life science venture capital investors Canaan… > Read More

Chimerix, Inc., Appoints Kenneth I. Moch Chief Operating Officer

   

RESEARCH TRIANGLE PARK, NC, July 16, 2009 – Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Kenneth I. Moch has joined the company as Chief Operating Officer.

Mr. Moch brings more than 25 years of experience… > Read More

Chimerix Joins International Network of Organizations to Cure Malaria

   

RESEARCH TRIANGLE PARK, NC, April 2, 2009 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has joined the Medicines for Malaria Venture (MMV) and its network of public-private partnerships… > Read More

2008

Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001

   

- CMX001 is an Orally Available Broad Spectrum Antiviral Being Investigated for the Treatment of dsDNA Viruses Including Smallpox, BK Virus, CMV and Adenovirus -

RESEARCH TRIANGLE PARK, NC, January 6, 2008 – Chimerix, Inc., a biotechnology company… > Read More

Chimerix Appoints Neil Frazer, M.B., FRCA, FFPM as Chief Medical Officer

   

RESEARCH TRIANGLE PARK, NC - January 3, 2008 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM  has joined the company as Chief Medical Officer.

Prior… > Read More

 1 2 3 >